Two Sigma Investments LP Purchases 91,205 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)

Two Sigma Investments LP lifted its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) by 212.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 134,175 shares of the biopharmaceutical company’s stock after purchasing an additional 91,205 shares during the quarter. Two Sigma Investments LP owned about 1.10% of Corbus Pharmaceuticals worth $1,583,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in CRBP. HealthInvest Partners AB increased its holdings in shares of Corbus Pharmaceuticals by 41.3% in the fourth quarter. HealthInvest Partners AB now owns 98,304 shares of the biopharmaceutical company’s stock worth $1,188,000 after purchasing an additional 28,731 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Corbus Pharmaceuticals by 4.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 97,882 shares of the biopharmaceutical company’s stock worth $1,155,000 after purchasing an additional 4,239 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Corbus Pharmaceuticals by 5.5% in the fourth quarter. Geode Capital Management LLC now owns 263,532 shares of the biopharmaceutical company’s stock worth $3,110,000 after purchasing an additional 13,773 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Corbus Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 2,195 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Corbus Pharmaceuticals by 769.4% in the fourth quarter. Renaissance Technologies LLC now owns 139,100 shares of the biopharmaceutical company’s stock worth $1,641,000 after purchasing an additional 123,100 shares during the last quarter. 64.64% of the stock is owned by institutional investors.

Corbus Pharmaceuticals Price Performance

Shares of NASDAQ:CRBP opened at $8.30 on Wednesday. Corbus Pharmaceuticals Holdings, Inc. has a 1 year low of $4.64 and a 1 year high of $61.90. The business has a 50 day simple moving average of $6.67 and a two-hundred day simple moving average of $9.62. The firm has a market capitalization of $101.57 million, a PE ratio of -1.77 and a beta of 3.19.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.13). Equities research analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post -4.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CRBP shares. Jefferies Financial Group reduced their price objective on Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. William Blair started coverage on Corbus Pharmaceuticals in a research note on Friday, February 28th. They set an “outperform” rating on the stock. Wall Street Zen raised Corbus Pharmaceuticals to a “sell” rating in a research note on Thursday, March 6th. Oppenheimer reduced their price objective on Corbus Pharmaceuticals from $60.00 to $56.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. Finally, B. Riley reissued a “buy” rating on shares of Corbus Pharmaceuticals in a research note on Wednesday, May 7th. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $50.88.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.